<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02515630</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-352-1672</org_study_id>
    <nct_id>NCT02515630</nct_id>
  </id_info>
  <brief_title>Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)</brief_title>
  <official_title>A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sierra Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sierra Oncology, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the transfusion independence response rate in transfusion-dependent&#xD;
      adults with myelofibrosis after treatment with momelotinib (MMB).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2016</start_date>
  <completion_date type="Actual">August 15, 2017</completion_date>
  <primary_completion_date type="Actual">July 18, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transfusion Independence Response by Week 24</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion Response Rate by Week 24</measure>
    <time_frame>From baseline to Week 24</time_frame>
    <description>The percentage of subjects who became transfusion independent for ≥ 8 weeks, defined as no RBC transfusions for at least an 8-week period at any time on study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Splenic Response Rate at Week 24</measure>
    <time_frame>Measured at Week 24</time_frame>
    <description>The percentage of subjects who achieved a ≥ 35% reduction in spleen volume from baseline as measured by MRI at Week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rate in Total Symptom Score (TSS) at Week 24</measure>
    <time_frame>Measured at Week 24</time_frame>
    <description>The percentage of subjects achieving a ≥ 50% reduction from baseline in TSS at Week 24, as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary. Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70. The questionnaire was completed daily on an electronic diary device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change</measure>
    <time_frame>At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Hepcidin daily change (in nM) was calculated as the predose value subtracted from the 6 hours postdose value at each study visit. Daily hepcidin change at the baseline visit was the difference between 2 values obtained 6 hours apart. No momelotinib was administered on that day.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Trough Hepcidin</measure>
    <time_frame>At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Median hepcidin at trough was assessed predose at each study visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Serum Iron</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in serum iron, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Hemoglobin</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in hemoglobin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in total iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Reticulocytes</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in reticulocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes%</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in reticulocytes/erythrocytes%, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Erythropoietin</measure>
    <time_frame>At Weeks 8 and 20</time_frame>
    <description>Percent change in erythropoietin at Weeks 8 and 20. The baseline erythropoietin value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Erythrocytes</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in erythrocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Hematocrit</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in hematocrit, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Ferritin</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in ferritin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in soluble transferrin receptor, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Transferrin Saturation</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in transferrin saturation, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in unsaturated iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Platelets</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in platelets, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Leukocytes</measure>
    <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
    <description>Percent change from baseline in leukocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Markers of Iron Metabolism and Anemia - Blasts</measure>
    <time_frame>At Weeks 2 and 4</time_frame>
    <description>Change from baseline in % blasts at Weeks 2 and 4. The baseline % blasts value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Liver Iron Content</measure>
    <time_frame>Measured at Week 24</time_frame>
    <description>Percent change from baseline in liver iron content assessed by MRI. The baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pharmacodynamics Biomarker - pSTAT3</measure>
    <time_frame>On Day 1 and at Weeks 4 and 24</time_frame>
    <description>Percent change in %pSTAT stimulated CD3+/4+ T cell at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Pharmacodynamics Biomarker - pSTAT3/tSTAT3 Ratio</measure>
    <time_frame>On Day 1 and at Weeks 4 and 24</time_frame>
    <description>Percent change in %pSTAT/%tSTAT Stimulated CD3+/4+ T cell ratio at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory Markers - C-Reactive Protein (CRP)</measure>
    <time_frame>At Weeks 2, 12 and 24</time_frame>
    <description>Percent change in C-reactive protein at Weeks 2, 12 and 24. The baseline C-reactive protein value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Primary Myelofibrosis (PMF)</condition>
  <condition>Post-polycythemia Vera (Post-PV) Myelofibrosis</condition>
  <condition>Postessential Thrombocythemia (Post-ET) Myelofibrosis</condition>
  <arm_group>
    <arm_group_label>Momelotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MMB for 24 weeks (± 7 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMB</intervention_name>
    <description>Momelotinib (MMB) tablet administered orally once daily</description>
    <arm_group_label>Momelotinib</arm_group_label>
    <other_name>GS-0387</other_name>
    <other_name>CYT387</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of PMF or Post PV/ET-MF&#xD;
&#xD;
          -  Requires myelofibrosis therapy, in the opinion of the investigator&#xD;
&#xD;
          -  High risk OR intermediate-2 risk defined by dynamic international prognostic scoring&#xD;
             system (DIPSS) OR intermediate-1 risk defined by DIPSS and associated with symptomatic&#xD;
             splenomegaly and/or hepatomegaly&#xD;
&#xD;
          -  Transfusion dependent at baseline, defined as ≥ 4 U red blood cell (RBC) transfusion&#xD;
             in the 8 weeks prior to first dose of MMB&#xD;
&#xD;
          -  Acceptable organ function as evidenced by the following:&#xD;
&#xD;
               -  Platelet Count ≥ 50 x 10^9/L&#xD;
&#xD;
               -  Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3&#xD;
                  x upper limit of normal (ULN) or AST or ALT ≤ 5 x ULN if liver is involved by&#xD;
                  disease process as judged by the investigator&#xD;
&#xD;
               -  Serum creatinine ≤ 2.0 mg/dL or calculated creatinine clearance of ≥ 60 mL/min&#xD;
&#xD;
               -  Direct bilirubin ≤ 2.0 x ULN&#xD;
&#xD;
          -  Life expectancy of &gt; 24 weeks&#xD;
&#xD;
          -  Males and females of childbearing potential who engage in heterosexual intercourse&#xD;
             must agree to use protocol specified method(s) of contraception&#xD;
&#xD;
          -  Lactating females must agree to discontinue nursing before MMB administration&#xD;
&#xD;
          -  Able to understand and willing to sign the informed consent form&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior splenectomy&#xD;
&#xD;
          -  Splenic irradiation within 3 months prior to the first dose of MMB&#xD;
&#xD;
          -  Prior treatment with MMB&#xD;
&#xD;
          -  Known positive status of human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Chronic active or acute viral hepatitis A, B, or C infection (testing required for&#xD;
             hepatitis B and C), or hepatitis B or C carrier&#xD;
&#xD;
          -  Use of strong cytochrome P450 3A4 (CYP3A4) inducer within 2 weeks prior to the first&#xD;
             dose of MMB&#xD;
&#xD;
          -  Uncontrolled intercurrent illness per protocol&#xD;
&#xD;
          -  Treatment with a Janus kinase (JAK) inhibitor within 21 days of the planned first dose&#xD;
             of MMB&#xD;
&#xD;
          -  Presence of peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events&#xD;
             (CTCAE) Grade 2&#xD;
&#xD;
          -  Unwilling or unable to undergo a MRI per requirements in the study protocol&#xD;
&#xD;
          -  Unwilling to consent to genomics sampling&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 3, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2015</study_first_posted>
  <results_first_submitted>July 2, 2020</results_first_submitted>
  <results_first_submitted_qc>January 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 20, 2021</results_first_posted>
  <disposition_first_submitted>July 2, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 2, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 5, 2018</disposition_first_posted>
  <last_update_submitted>January 12, 2021</last_update_submitted>
  <last_update_submitted_qc>January 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycythemia Vera</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Polycythemia</mesh_term>
    <mesh_term>Thrombocytosis</mesh_term>
    <mesh_term>Thrombocythemia, Essential</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02515630/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/30/NCT02515630/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study enrolled transfusion-dependent myelofibrosis patients at oncology centers in the United States and Canada. Following completion of the 24-week study period, patients who were benefiting had the option to continue maintenance momelotinib treatment in an open-label extension study (NCT02124746).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Momelotinib (MMB)</title>
          <description>Subjects received oral MMB at a starting dose of 200 mg once daily for 24 weeks (± 7 days) on study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transfusion Independence Responders</title>
          <description>Subjects who became transfusion independent by Week 24</description>
        </group>
        <group group_id="B2">
          <title>Transfusion Independence Non-Responders</title>
          <description>Subjects who did not become transfusion independent by Week 24</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="10.0"/>
                    <measurement group_id="B2" value="72" spread="7.5"/>
                    <measurement group_id="B3" value="70" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Permitted</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spleen Volume</title>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2132.2" spread="1439.5"/>
                    <measurement group_id="B2" value="2018.1" spread="1248.5"/>
                    <measurement group_id="B3" value="2057.1" spread="1299.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Symptom Score</title>
          <description>Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.00" spread="16.14"/>
                    <measurement group_id="B2" value="21.73" spread="13.97"/>
                    <measurement group_id="B3" value="20.73" spread="14.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>RBC Units Transfused within 8 weeks prior to Enrollment</title>
          <units>Units of red blood cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" spread="1.9"/>
                    <measurement group_id="B2" value="7" spread="2.2"/>
                    <measurement group_id="B3" value="6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hepcidin</title>
          <units>nM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" lower_limit="9.6" upper_limit="33.9"/>
                    <measurement group_id="B2" value="42.4" lower_limit="27.4" upper_limit="64.9"/>
                    <measurement group_id="B3" value="36.6" lower_limit="18.6" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum iron</title>
          <units>ug/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96.0" lower_limit="56.0" upper_limit="123.0"/>
                    <measurement group_id="B2" value="127.0" lower_limit="105.0" upper_limit="174.0"/>
                    <measurement group_id="B3" value="119.0" lower_limit="84.0" upper_limit="165.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin</title>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.5" lower_limit="7.6" upper_limit="9.4"/>
                    <measurement group_id="B2" value="7.8" lower_limit="7.3" upper_limit="8.4"/>
                    <measurement group_id="B3" value="8.0" lower_limit="7.4" upper_limit="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total iron binding capacity</title>
          <units>ug/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="214.5" lower_limit="178.0" upper_limit="239.0"/>
                    <measurement group_id="B2" value="201.0" lower_limit="181.0" upper_limit="269.0"/>
                    <measurement group_id="B3" value="205.0" lower_limit="181.0" upper_limit="253.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reticulocytes</title>
          <units>cells*10^6/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.096" lower_limit="0.055" upper_limit="0.127"/>
                    <measurement group_id="B2" value="0.067" lower_limit="0.039" upper_limit="0.094"/>
                    <measurement group_id="B3" value="0.071" lower_limit="0.043" upper_limit="0.102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Reticulocytes/erythrocytes</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="1.8" upper_limit="4.3"/>
                    <measurement group_id="B2" value="2.2" lower_limit="1.4" upper_limit="3.2"/>
                    <measurement group_id="B3" value="2.4" lower_limit="1.7" upper_limit="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythropoietin</title>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="238.7" lower_limit="63.3" upper_limit="499.4"/>
                    <measurement group_id="B2" value="88.1" lower_limit="27.5" upper_limit="287.6"/>
                    <measurement group_id="B3" value="109.8" lower_limit="30.0" upper_limit="493.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocytes</title>
          <units>cells*10^6/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" lower_limit="2.8" upper_limit="3.2"/>
                    <measurement group_id="B2" value="2.8" lower_limit="2.6" upper_limit="3.3"/>
                    <measurement group_id="B3" value="2.9" lower_limit="2.6" upper_limit="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hematocrit</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" lower_limit="25.0" upper_limit="28.0"/>
                    <measurement group_id="B2" value="24.0" lower_limit="22.0" upper_limit="28.0"/>
                    <measurement group_id="B3" value="25.0" lower_limit="22.0" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ferritin</title>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="605.9" lower_limit="372.7" upper_limit="1018.5"/>
                    <measurement group_id="B2" value="1259.4" lower_limit="441.6" upper_limit="2321.5"/>
                    <measurement group_id="B3" value="1008.9" lower_limit="441.6" upper_limit="1634.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Soluble transferrin receptor</title>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="1.6" upper_limit="5.8"/>
                    <measurement group_id="B2" value="1.3" lower_limit="0.7" upper_limit="2.1"/>
                    <measurement group_id="B3" value="1.6" lower_limit="1.0" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transferrin saturation</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.0" lower_limit="33.0" upper_limit="54.0"/>
                    <measurement group_id="B2" value="56.5" lower_limit="47.5" upper_limit="63.0"/>
                    <measurement group_id="B3" value="53.0" lower_limit="42.0" upper_limit="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unsaturated iron binding capacity</title>
          <units>ug/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113.5" lower_limit="30.0" upper_limit="151.0"/>
                    <measurement group_id="B2" value="81.0" lower_limit="37.0" upper_limit="124.0"/>
                    <measurement group_id="B3" value="92.0" lower_limit="37.0" upper_limit="127.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelets</title>
          <units>cells*10^3/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="190.5" lower_limit="72.0" upper_limit="262.0"/>
                    <measurement group_id="B2" value="134.0" lower_limit="106.0" upper_limit="211.0"/>
                    <measurement group_id="B3" value="146.0" lower_limit="106.0" upper_limit="222.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Leukocytes</title>
          <units>cells*10^3/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.4" lower_limit="3.8" upper_limit="7.7"/>
                    <measurement group_id="B2" value="8.5" lower_limit="4.5" upper_limit="11.4"/>
                    <measurement group_id="B3" value="6.4" lower_limit="4.5" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blasts</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" lower_limit="NA" upper_limit="NA">No blasts measured</measurement>
                    <measurement group_id="B2" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                    <measurement group_id="B3" value="2.0" lower_limit="2.0" upper_limit="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver Iron Content</title>
          <units>mg/g</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" lower_limit="1.6" upper_limit="4.0"/>
                    <measurement group_id="B2" value="4.2" lower_limit="2.6" upper_limit="11.3"/>
                    <measurement group_id="B3" value="3.5" lower_limit="2.3" upper_limit="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%pSTAT Stimulated CD3+/4+ T cell</title>
          <units>%</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.1" lower_limit="76.9" upper_limit="87.1"/>
                    <measurement group_id="B2" value="77.8" lower_limit="60.3" upper_limit="91.5"/>
                    <measurement group_id="B3" value="79.8" lower_limit="67.6" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>%pSTAT %tSTAT Stimulated CD3+/4+ T cell Ratio</title>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.9" lower_limit="0.9" upper_limit="1.0"/>
                    <measurement group_id="B2" value="0.8" lower_limit="0.6" upper_limit="1.0"/>
                    <measurement group_id="B3" value="0.9" lower_limit="0.7" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-Reactive Protein</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.7" lower_limit="0.4" upper_limit="1.8"/>
                    <measurement group_id="B2" value="1.8" lower_limit="0.6" upper_limit="4.5"/>
                    <measurement group_id="B3" value="1.2" lower_limit="0.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Transfusion Independence Response by Week 24</title>
        <description>The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.</description>
        <time_frame>From baseline to Week 24</time_frame>
        <population>Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that 6 subjects discontinued prior to Week 12 and could not be evaluated over the minimum period required for assessment of the endpoint (12 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Transfusion Independence Response by Week 24</title>
          <description>The percentage of subjects who became transfusion independent for ≥ 12 weeks at any time on study. A subject was considered transfusion independent on study if no RBC transfusion occurred in any 12-week period during the 24-week treatment period.</description>
          <population>Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that 6 subjects discontinued prior to Week 12 and could not be evaluated over the minimum period required for assessment of the endpoint (12 weeks).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.1" lower_limit="22.0" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transfusion Response Rate by Week 24</title>
        <description>The percentage of subjects who became transfusion independent for ≥ 8 weeks, defined as no RBC transfusions for at least an 8-week period at any time on study.</description>
        <time_frame>From baseline to Week 24</time_frame>
        <population>Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that 3 subjects discontinued prior to Week 8 and could not be evaluated over the minimum period required for assessment of the endpoint (8 weeks).</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Transfusion Response Rate by Week 24</title>
          <description>The percentage of subjects who became transfusion independent for ≥ 8 weeks, defined as no RBC transfusions for at least an 8-week period at any time on study.</description>
          <population>Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that 3 subjects discontinued prior to Week 8 and could not be evaluated over the minimum period required for assessment of the endpoint (8 weeks).</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.0" lower_limit="26.2" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Splenic Response Rate at Week 24</title>
        <description>The percentage of subjects who achieved a ≥ 35% reduction in spleen volume from baseline as measured by MRI at Week 24.</description>
        <time_frame>Measured at Week 24</time_frame>
        <population>Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that spleen volume at Week 24 was not available for 15 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Splenic Response Rate at Week 24</title>
          <description>The percentage of subjects who achieved a ≥ 35% reduction in spleen volume from baseline as measured by MRI at Week 24.</description>
          <population>Assessed in the Safety Analysis Set, which includes all subjects who received ≥ 1 dose of momelotinib. Note that spleen volume at Week 24 was not available for 15 subjects.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" lower_limit="4.9" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rate in Total Symptom Score (TSS) at Week 24</title>
        <description>The percentage of subjects achieving a ≥ 50% reduction from baseline in TSS at Week 24, as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary. Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70. The questionnaire was completed daily on an electronic diary device.</description>
        <time_frame>Measured at Week 24</time_frame>
        <population>There were 3 subjects with missing TSS at baseline who were excluded from the analysis. Note that of the 38 subjects evaluated, 17 were missing Week 24 TSS assessments.</population>
        <group_list>
          <group group_id="O1">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Response Rate in Total Symptom Score (TSS) at Week 24</title>
          <description>The percentage of subjects achieving a ≥ 50% reduction from baseline in TSS at Week 24, as measured by the modified Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPNSAF TSS) diary. Total symptom score was assessed using the modified MPN-SAF TSS Version 2, an 8-item questionnaire developed to assess symptom burden and quality of life in patients with MPN. The modified MPN-SAF TSS contained 8 questions, 7 of which were summed to generate the score (the included questions related to tiredness, early satiety, abdominal discomfort, night sweats, itching, bone pain, and pain under the ribs on the left side). Each question is scored on a scale of 0-10, where higher numbers indicate more severe symptoms. For this study, the TSS scale ranges from 0 to 70. The questionnaire was completed daily on an electronic diary device.</description>
          <population>There were 3 subjects with missing TSS at baseline who were excluded from the analysis. Note that of the 38 subjects evaluated, 17 were missing Week 24 TSS assessments.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="7.1" upper_limit="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change</title>
        <description>Hepcidin daily change (in nM) was calculated as the predose value subtracted from the 6 hours postdose value at each study visit. Daily hepcidin change at the baseline visit was the difference between 2 values obtained 6 hours apart. No momelotinib was administered on that day.</description>
        <time_frame>At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Change From Baseline in Hepcidin Daily Change</title>
          <description>Hepcidin daily change (in nM) was calculated as the predose value subtracted from the 6 hours postdose value at each study visit. Daily hepcidin change at the baseline visit was the difference between 2 values obtained 6 hours apart. No momelotinib was administered on that day.</description>
          <units>nM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" lower_limit="-2.1" upper_limit="4.7"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-3.3" upper_limit="4.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-3.3" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" lower_limit="-10.2" upper_limit="-1.4"/>
                    <measurement group_id="O2" value="-11.2" lower_limit="-16.0" upper_limit="-5.8"/>
                    <measurement group_id="O3" value="-8.6" lower_limit="-14.4" upper_limit="-3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" lower_limit="-9.1" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-11.3" upper_limit="-1.2"/>
                    <measurement group_id="O3" value="-6.3" lower_limit="-9.2" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" lower_limit="-8.5" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-7.4" lower_limit="-9.6" upper_limit="-0.9"/>
                    <measurement group_id="O3" value="-5.4" lower_limit="-9.6" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" lower_limit="-7.3" upper_limit="-0.9"/>
                    <measurement group_id="O2" value="-5.2" lower_limit="-17.7" upper_limit="2.1"/>
                    <measurement group_id="O3" value="-4.4" lower_limit="-10.9" upper_limit="-0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-6.8" upper_limit="0.7"/>
                    <measurement group_id="O2" value="-5.7" lower_limit="-8.7" upper_limit="-0.9"/>
                    <measurement group_id="O3" value="-4.1" lower_limit="-8.4" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-6.4" upper_limit="0.7"/>
                    <measurement group_id="O2" value="-4.3" lower_limit="-15.1" upper_limit="1.9"/>
                    <measurement group_id="O3" value="-2.7" lower_limit="-8.5" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-6.6" upper_limit="4.2"/>
                    <measurement group_id="O2" value="-7.8" lower_limit="-12.5" upper_limit="-1.9"/>
                    <measurement group_id="O3" value="-5.3" lower_limit="-9.0" upper_limit="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-4.6" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-1.8" lower_limit="-7.8" upper_limit="0.1"/>
                    <measurement group_id="O3" value="-1.4" lower_limit="-6.0" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Trough Hepcidin</title>
        <description>Median hepcidin at trough was assessed predose at each study visit.</description>
        <time_frame>At baseline, Day 1, Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Trough Hepcidin</title>
          <description>Median hepcidin at trough was assessed predose at each study visit.</description>
          <units>nM</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" lower_limit="9.6" upper_limit="33.9"/>
                    <measurement group_id="O2" value="42.4" lower_limit="27.4" upper_limit="64.9"/>
                    <measurement group_id="O3" value="36.6" lower_limit="18.6" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" lower_limit="5.5" upper_limit="30.8"/>
                    <measurement group_id="O2" value="43.7" lower_limit="29.9" upper_limit="58.7"/>
                    <measurement group_id="O3" value="36.5" lower_limit="22.4" upper_limit="48.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.1" lower_limit="14.6" upper_limit="29.7"/>
                    <measurement group_id="O2" value="52.1" lower_limit="37.4" upper_limit="61.2"/>
                    <measurement group_id="O3" value="38.4" lower_limit="25.8" upper_limit="57.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" lower_limit="13.7" upper_limit="30.8"/>
                    <measurement group_id="O2" value="46.4" lower_limit="39.1" upper_limit="57.1"/>
                    <measurement group_id="O3" value="37.6" lower_limit="19.8" upper_limit="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.6" lower_limit="10.1" upper_limit="29.2"/>
                    <measurement group_id="O2" value="51.7" lower_limit="39.9" upper_limit="59.4"/>
                    <measurement group_id="O3" value="35.5" lower_limit="16.9" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.3" lower_limit="10.9" upper_limit="30.4"/>
                    <measurement group_id="O2" value="44.7" lower_limit="23.3" upper_limit="53.9"/>
                    <measurement group_id="O3" value="30.4" lower_limit="15.6" upper_limit="44.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.9" lower_limit="7.1" upper_limit="29.0"/>
                    <measurement group_id="O2" value="51.9" lower_limit="43.7" upper_limit="62.9"/>
                    <measurement group_id="O3" value="34.5" lower_limit="17.1" upper_limit="51.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" lower_limit="4.5" upper_limit="27.4"/>
                    <measurement group_id="O2" value="44.2" lower_limit="31.5" upper_limit="49.7"/>
                    <measurement group_id="O3" value="27.5" lower_limit="13.4" upper_limit="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="4.9" upper_limit="28.8"/>
                    <measurement group_id="O2" value="51.5" lower_limit="27.9" upper_limit="60.2"/>
                    <measurement group_id="O3" value="28.4" lower_limit="14.2" upper_limit="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Serum Iron</title>
        <description>Percent change from baseline in serum iron, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Serum Iron</title>
          <description>Percent change from baseline in serum iron, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="-14.6" upper_limit="73.2"/>
                    <measurement group_id="O2" value="5.9" lower_limit="-10.3" upper_limit="31.0"/>
                    <measurement group_id="O3" value="5.9" lower_limit="-11.8" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.8" lower_limit="1.8" upper_limit="108.1"/>
                    <measurement group_id="O2" value="5.7" lower_limit="-16.2" upper_limit="33.3"/>
                    <measurement group_id="O3" value="13.3" lower_limit="-12.7" upper_limit="57.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="-23.6" upper_limit="44.0"/>
                    <measurement group_id="O2" value="5.4" lower_limit="-15.6" upper_limit="42.0"/>
                    <measurement group_id="O3" value="6.4" lower_limit="-18.2" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-25.2" upper_limit="73.2"/>
                    <measurement group_id="O2" value="14.3" lower_limit="3.1" upper_limit="35.1"/>
                    <measurement group_id="O3" value="12.8" lower_limit="-7.9" upper_limit="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.5" lower_limit="-20.3" upper_limit="56.6"/>
                    <measurement group_id="O2" value="16.5" lower_limit="-19.3" upper_limit="30.7"/>
                    <measurement group_id="O3" value="8.9" lower_limit="-19.4" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.1" lower_limit="-17.8" upper_limit="41.7"/>
                    <measurement group_id="O2" value="9.9" lower_limit="-7.4" upper_limit="28.1"/>
                    <measurement group_id="O3" value="1.9" lower_limit="-17.8" upper_limit="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.1" lower_limit="-20.4" upper_limit="45.1"/>
                    <measurement group_id="O2" value="-5.1" lower_limit="-24.3" upper_limit="31.1"/>
                    <measurement group_id="O3" value="-6.6" lower_limit="-22.9" upper_limit="37.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Hemoglobin</title>
        <description>Percent change from baseline in hemoglobin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Hemoglobin</title>
          <description>Percent change from baseline in hemoglobin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change in from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="0.0" upper_limit="20.3"/>
                    <measurement group_id="O2" value="9.2" lower_limit="0.0" upper_limit="26.3"/>
                    <measurement group_id="O3" value="9.9" lower_limit="0.0" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.4" upper_limit="15.9"/>
                    <measurement group_id="O2" value="6.3" lower_limit="-1.2" upper_limit="20.6"/>
                    <measurement group_id="O3" value="6.9" lower_limit="-1.2" upper_limit="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="4.8" upper_limit="27.7"/>
                    <measurement group_id="O2" value="0.4" lower_limit="-7.7" upper_limit="14.2"/>
                    <measurement group_id="O3" value="5.6" lower_limit="-6.3" upper_limit="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.6" lower_limit="5.3" upper_limit="25.3"/>
                    <measurement group_id="O2" value="4.5" lower_limit="-12.5" upper_limit="13.4"/>
                    <measurement group_id="O3" value="7.5" lower_limit="-4.8" upper_limit="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" lower_limit="4.8" upper_limit="32.9"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-9.5" upper_limit="15.0"/>
                    <measurement group_id="O3" value="10.2" lower_limit="-6.3" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="5.3" upper_limit="28.9"/>
                    <measurement group_id="O2" value="6.9" lower_limit="-7.1" upper_limit="17.3"/>
                    <measurement group_id="O3" value="7.4" lower_limit="-3.9" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="-2.1" upper_limit="29.4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="-1.3" upper_limit="14.4"/>
                    <measurement group_id="O3" value="7.9" lower_limit="-1.4" upper_limit="17.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity</title>
        <description>Percent change from baseline in total iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Total Iron Binding Capacity</title>
          <description>Percent change from baseline in total iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="0.4" upper_limit="13.6"/>
                    <measurement group_id="O2" value="2.0" lower_limit="-5.5" upper_limit="8.9"/>
                    <measurement group_id="O3" value="2.8" lower_limit="-1.6" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="-2.5" upper_limit="15.7"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-9.6" upper_limit="10.7"/>
                    <measurement group_id="O3" value="2.2" lower_limit="-5.6" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="-2.7" upper_limit="10.3"/>
                    <measurement group_id="O2" value="0.6" lower_limit="-7.4" upper_limit="13.7"/>
                    <measurement group_id="O3" value="2.4" lower_limit="-6.6" upper_limit="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="-3.9" upper_limit="12.6"/>
                    <measurement group_id="O2" value="2.4" lower_limit="-5.9" upper_limit="20.2"/>
                    <measurement group_id="O3" value="6.6" lower_limit="-5.5" upper_limit="15.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" lower_limit="-3.2" upper_limit="9.8"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-10.0" upper_limit="14.2"/>
                    <measurement group_id="O3" value="3.6" lower_limit="-5.3" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="3.4" upper_limit="22.1"/>
                    <measurement group_id="O2" value="5.5" lower_limit="-11.6" upper_limit="15.4"/>
                    <measurement group_id="O3" value="10.6" lower_limit="1.6" upper_limit="17.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="3.6" upper_limit="15.8"/>
                    <measurement group_id="O2" value="0.5" lower_limit="-8.4" upper_limit="10.7"/>
                    <measurement group_id="O3" value="5.5" lower_limit="-5.9" upper_limit="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Reticulocytes</title>
        <description>Percent change from baseline in reticulocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Reticulocytes</title>
          <description>Percent change from baseline in reticulocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" lower_limit="-6.7" upper_limit="67.5"/>
                    <measurement group_id="O2" value="-9.6" lower_limit="-26.0" upper_limit="26.4"/>
                    <measurement group_id="O3" value="2.9" lower_limit="-23.6" upper_limit="36.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.8" lower_limit="4.0" upper_limit="40.7"/>
                    <measurement group_id="O2" value="5.5" lower_limit="-32.7" upper_limit="46.4"/>
                    <measurement group_id="O3" value="7.5" lower_limit="-29.3" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="13.2" upper_limit="35.0"/>
                    <measurement group_id="O2" value="-16.0" lower_limit="-30.6" upper_limit="28.4"/>
                    <measurement group_id="O3" value="15.6" lower_limit="-24.5" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" lower_limit="-6.3" upper_limit="45.1"/>
                    <measurement group_id="O2" value="-9.5" lower_limit="-34.5" upper_limit="33.3"/>
                    <measurement group_id="O3" value="4.8" lower_limit="-17.3" upper_limit="44.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2" lower_limit="-22.1" upper_limit="58.5"/>
                    <measurement group_id="O2" value="8.8" lower_limit="-24.0" upper_limit="35.5"/>
                    <measurement group_id="O3" value="18.3" lower_limit="-23.1" upper_limit="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" lower_limit="-35.6" upper_limit="70.4"/>
                    <measurement group_id="O2" value="7.7" lower_limit="-48.6" upper_limit="27.7"/>
                    <measurement group_id="O3" value="16.3" lower_limit="-44.8" upper_limit="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.9" lower_limit="11.5" upper_limit="58.3"/>
                    <measurement group_id="O2" value="-0.6" lower_limit="-32.0" upper_limit="67.8"/>
                    <measurement group_id="O3" value="24.1" lower_limit="-12.0" upper_limit="58.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes%</title>
        <description>Percent change from baseline in reticulocytes/erythrocytes%, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Reticulocytes/Erythrocytes%</title>
          <description>Percent change from baseline in reticulocytes/erythrocytes%, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="-16.7" upper_limit="42.6"/>
                    <measurement group_id="O2" value="-16.3" lower_limit="-30.1" upper_limit="23.6"/>
                    <measurement group_id="O3" value="-8.0" lower_limit="-28.1" upper_limit="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="-7.0" upper_limit="20.4"/>
                    <measurement group_id="O2" value="1.5" lower_limit="-36.3" upper_limit="29.6"/>
                    <measurement group_id="O3" value="4.1" lower_limit="-29.9" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="-5.6" upper_limit="33.3"/>
                    <measurement group_id="O2" value="-11.1" lower_limit="-35.3" upper_limit="27.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-21.2" upper_limit="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="-11.1" upper_limit="16.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-31.6" upper_limit="42.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-29.4" upper_limit="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="-22.9" upper_limit="33.3"/>
                    <measurement group_id="O2" value="18.7" lower_limit="-30.0" upper_limit="50.0"/>
                    <measurement group_id="O3" value="7.8" lower_limit="-29.0" upper_limit="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-34.3" upper_limit="21.4"/>
                    <measurement group_id="O2" value="14.6" lower_limit="-43.8" upper_limit="46.2"/>
                    <measurement group_id="O3" value="11.1" lower_limit="-42.1" upper_limit="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="-2.9" upper_limit="24.1"/>
                    <measurement group_id="O2" value="-7.8" lower_limit="-34.2" upper_limit="72.6"/>
                    <measurement group_id="O3" value="-2.6" lower_limit="-11.8" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Erythropoietin</title>
        <description>Percent change in erythropoietin at Weeks 8 and 20. The baseline erythropoietin value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 8 and 20</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Erythropoietin</title>
          <description>Percent change in erythropoietin at Weeks 8 and 20. The baseline erythropoietin value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.8" lower_limit="-55.6" upper_limit="-6.8"/>
                    <measurement group_id="O2" value="-8.1" lower_limit="-47.7" upper_limit="31.3"/>
                    <measurement group_id="O3" value="-24.5" lower_limit="-55.4" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-45.0" lower_limit="-63.4" upper_limit="-2.0"/>
                    <measurement group_id="O2" value="8.5" lower_limit="-16.2" upper_limit="82.9"/>
                    <measurement group_id="O3" value="-4.4" lower_limit="-60.2" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Erythrocytes</title>
        <description>Percent change from baseline in erythrocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Erythrocytes</title>
          <description>Percent change from baseline in erythrocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="0.0" upper_limit="20.0"/>
                    <measurement group_id="O2" value="3.4" lower_limit="-6.1" upper_limit="12.1"/>
                    <measurement group_id="O3" value="3.4" lower_limit="-6.1" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="-8.8" upper_limit="13.3"/>
                    <measurement group_id="O2" value="3.6" lower_limit="-3.6" upper_limit="21.5"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-3.7" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="-2.0" upper_limit="23.3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-13.1" upper_limit="13.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="-6.1" upper_limit="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="-3.6" upper_limit="26.7"/>
                    <measurement group_id="O2" value="3.6" lower_limit="-13.8" upper_limit="11.4"/>
                    <measurement group_id="O3" value="3.4" lower_limit="-10.0" upper_limit="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-8.8" upper_limit="26.7"/>
                    <measurement group_id="O2" value="-6.9" lower_limit="-9.2" upper_limit="6.5"/>
                    <measurement group_id="O3" value="-2.9" lower_limit="-8.8" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-12.0" upper_limit="26.7"/>
                    <measurement group_id="O2" value="-3.4" lower_limit="-13.8" upper_limit="7.7"/>
                    <measurement group_id="O3" value="-3.4" lower_limit="-12.1" upper_limit="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" lower_limit="-9.7" upper_limit="26.7"/>
                    <measurement group_id="O2" value="3.3" lower_limit="-7.1" upper_limit="11.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-9.7" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Hematocrit</title>
        <description>Percent change from baseline in hematocrit, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Hematocrit</title>
          <description>Percent change from baseline in hematocrit, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="-4.3" upper_limit="18.5"/>
                    <measurement group_id="O2" value="4.0" lower_limit="-4.8" upper_limit="11.1"/>
                    <measurement group_id="O3" value="4.5" lower_limit="-4.8" upper_limit="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="-5.6" upper_limit="10.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-4.3" upper_limit="21.4"/>
                    <measurement group_id="O3" value="3.4" lower_limit="-4.3" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="3.6" upper_limit="25.9"/>
                    <measurement group_id="O2" value="-1.7" lower_limit="-14.6" upper_limit="14.8"/>
                    <measurement group_id="O3" value="4.0" lower_limit="-7.1" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="-3.1" upper_limit="30.8"/>
                    <measurement group_id="O2" value="1.8" lower_limit="-13.0" upper_limit="14.8"/>
                    <measurement group_id="O3" value="3.6" lower_limit="-8.0" upper_limit="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" lower_limit="-3.2" upper_limit="28.6"/>
                    <measurement group_id="O2" value="-4.2" lower_limit="-8.3" upper_limit="8.2"/>
                    <measurement group_id="O3" value="3.8" lower_limit="-7.7" upper_limit="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" lower_limit="-3.2" upper_limit="26.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-12.0" upper_limit="4.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-7.9" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="-3.6" upper_limit="28.6"/>
                    <measurement group_id="O2" value="2.3" lower_limit="-9.1" upper_limit="9.1"/>
                    <measurement group_id="O3" value="4.5" lower_limit="-8.3" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Ferritin</title>
        <description>Percent change from baseline in ferritin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Ferritin</title>
          <description>Percent change from baseline in ferritin, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="-11.2" upper_limit="35.9"/>
                    <measurement group_id="O2" value="8.8" lower_limit="-0.2" upper_limit="25.3"/>
                    <measurement group_id="O3" value="8.8" lower_limit="-7.4" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.1" lower_limit="-6.8" upper_limit="32.9"/>
                    <measurement group_id="O2" value="8.3" lower_limit="-3.5" upper_limit="38.8"/>
                    <measurement group_id="O3" value="13.6" lower_limit="-3.8" upper_limit="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="-24.1" upper_limit="15.9"/>
                    <measurement group_id="O2" value="30.4" lower_limit="-5.6" upper_limit="38.7"/>
                    <measurement group_id="O3" value="16.7" lower_limit="-10.1" upper_limit="32.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-11.2" upper_limit="11.3"/>
                    <measurement group_id="O2" value="26.4" lower_limit="4.3" upper_limit="52.0"/>
                    <measurement group_id="O3" value="11.3" lower_limit="-10.0" upper_limit="31.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="-24.6" upper_limit="8.0"/>
                    <measurement group_id="O2" value="21.6" lower_limit="0.7" upper_limit="100.9"/>
                    <measurement group_id="O3" value="6.7" lower_limit="-8.7" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="-42.9" upper_limit="23.1"/>
                    <measurement group_id="O2" value="13.6" lower_limit="-10.0" upper_limit="74.6"/>
                    <measurement group_id="O3" value="7.0" lower_limit="-33.6" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.2" lower_limit="-40.2" upper_limit="6.6"/>
                    <measurement group_id="O2" value="15.4" lower_limit="-20.7" upper_limit="59.7"/>
                    <measurement group_id="O3" value="1.4" lower_limit="-27.2" upper_limit="42.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor</title>
        <description>Percent change from baseline in soluble transferrin receptor, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Soluble Transferrin Receptor</title>
          <description>Percent change from baseline in soluble transferrin receptor, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="-14.7" upper_limit="18.1"/>
                    <measurement group_id="O2" value="-4.9" lower_limit="-12.8" upper_limit="6.3"/>
                    <measurement group_id="O3" value="-4.8" lower_limit="-14.1" upper_limit="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" lower_limit="-7.0" upper_limit="26.2"/>
                    <measurement group_id="O2" value="8.8" lower_limit="-16.6" upper_limit="31.5"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-16.6" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="-15.3" upper_limit="24.0"/>
                    <measurement group_id="O2" value="11.0" lower_limit="-15.1" upper_limit="37.2"/>
                    <measurement group_id="O3" value="7.4" lower_limit="-15.3" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-18.3" upper_limit="13.5"/>
                    <measurement group_id="O2" value="11.1" lower_limit="2.0" upper_limit="38.8"/>
                    <measurement group_id="O3" value="10.7" lower_limit="-13.5" upper_limit="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" lower_limit="-17.3" upper_limit="19.2"/>
                    <measurement group_id="O2" value="14.9" lower_limit="-9.1" upper_limit="32.3"/>
                    <measurement group_id="O3" value="1.3" lower_limit="-9.1" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" lower_limit="-11.2" upper_limit="10.6"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-7.4" upper_limit="21.2"/>
                    <measurement group_id="O3" value="-1.2" lower_limit="-11.2" upper_limit="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" lower_limit="-15.5" upper_limit="10.0"/>
                    <measurement group_id="O2" value="19.7" lower_limit="-24.2" upper_limit="30.8"/>
                    <measurement group_id="O3" value="-1.8" lower_limit="-16.7" upper_limit="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Transferrin Saturation</title>
        <description>Percent change from baseline in transferrin saturation, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Transferrin Saturation</title>
          <description>Percent change from baseline in transferrin saturation, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="-15.2" upper_limit="52.1"/>
                    <measurement group_id="O2" value="13.5" lower_limit="-6.7" upper_limit="35.6"/>
                    <measurement group_id="O3" value="10.3" lower_limit="-8.3" upper_limit="44.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" lower_limit="4.2" upper_limit="75.0"/>
                    <measurement group_id="O2" value="9.7" lower_limit="-17.2" upper_limit="36.7"/>
                    <measurement group_id="O3" value="10.5" lower_limit="-4.8" upper_limit="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="-21.7" upper_limit="33.3"/>
                    <measurement group_id="O2" value="-5.0" lower_limit="-23.1" upper_limit="26.2"/>
                    <measurement group_id="O3" value="-3.1" lower_limit="-22.4" upper_limit="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.9" lower_limit="-18.6" upper_limit="52.9"/>
                    <measurement group_id="O2" value="16.4" lower_limit="-3.8" upper_limit="26.3"/>
                    <measurement group_id="O3" value="14.1" lower_limit="-18.3" upper_limit="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.2" lower_limit="-22.2" upper_limit="40.7"/>
                    <measurement group_id="O2" value="-13.5" lower_limit="-24.6" upper_limit="33.3"/>
                    <measurement group_id="O3" value="-10.4" lower_limit="-24.6" upper_limit="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" lower_limit="-20.7" upper_limit="36.4"/>
                    <measurement group_id="O2" value="-20.8" lower_limit="-40.4" upper_limit="8.3"/>
                    <measurement group_id="O3" value="-13.3" lower_limit="-31.9" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.3" lower_limit="-22.1" upper_limit="23.7"/>
                    <measurement group_id="O2" value="-20.8" lower_limit="-31.7" upper_limit="25.0"/>
                    <measurement group_id="O3" value="-11.9" lower_limit="-25.0" upper_limit="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity</title>
        <description>Percent change from baseline in unsaturated iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Unsaturated Iron Binding Capacity</title>
          <description>Percent change from baseline in unsaturated iron binding capacity, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-39.4" upper_limit="13.2"/>
                    <measurement group_id="O2" value="-5.1" lower_limit="-31.1" upper_limit="14.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-31.5" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" lower_limit="-24.3" upper_limit="1.9"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-35.7" upper_limit="34.0"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-25.3" upper_limit="28.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" lower_limit="-25.0" upper_limit="28.0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-40.2" upper_limit="31.8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-29.9" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9" lower_limit="-17.4" upper_limit="31.4"/>
                    <measurement group_id="O2" value="-18.4" lower_limit="-33.6" upper_limit="7.0"/>
                    <measurement group_id="O3" value="-1.6" lower_limit="-32.3" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" lower_limit="-22.4" upper_limit="34.7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-49.2" upper_limit="21.4"/>
                    <measurement group_id="O3" value="2.6" lower_limit="-35.6" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5" lower_limit="-12.0" upper_limit="62.8"/>
                    <measurement group_id="O2" value="5.1" lower_limit="-39.8" upper_limit="44.0"/>
                    <measurement group_id="O3" value="14.2" lower_limit="-15.9" upper_limit="46.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0" lower_limit="2.5" upper_limit="32.2"/>
                    <measurement group_id="O2" value="6.9" lower_limit="-35.7" upper_limit="64.9"/>
                    <measurement group_id="O3" value="12.0" lower_limit="-11.3" upper_limit="64.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Platelets</title>
        <description>Percent change from baseline in platelets, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Platelets</title>
          <description>Percent change from baseline in platelets, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4" lower_limit="-25.4" upper_limit="48.9"/>
                    <measurement group_id="O2" value="-24.4" lower_limit="-41.8" upper_limit="6.3"/>
                    <measurement group_id="O3" value="-9.5" lower_limit="-37.4" upper_limit="32.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-25.5" upper_limit="49.1"/>
                    <measurement group_id="O2" value="-29.7" lower_limit="-43.7" upper_limit="-4.1"/>
                    <measurement group_id="O3" value="-26.3" lower_limit="-35.9" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.7" lower_limit="-1.3" upper_limit="57.2"/>
                    <measurement group_id="O2" value="-33.6" lower_limit="-48.2" upper_limit="3.3"/>
                    <measurement group_id="O3" value="-12.0" lower_limit="-40.3" upper_limit="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1" lower_limit="7.9" upper_limit="83.7"/>
                    <measurement group_id="O2" value="-27.7" lower_limit="-49.0" upper_limit="-11.5"/>
                    <measurement group_id="O3" value="-11.4" lower_limit="-39.9" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" lower_limit="2.3" upper_limit="80.0"/>
                    <measurement group_id="O2" value="-26.1" lower_limit="-48.0" upper_limit="-6.2"/>
                    <measurement group_id="O3" value="-6.2" lower_limit="-31.3" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.0" lower_limit="-6.9" upper_limit="41.4"/>
                    <measurement group_id="O2" value="-36.2" lower_limit="-67.1" upper_limit="-10.7"/>
                    <measurement group_id="O3" value="-14.3" lower_limit="-37.8" upper_limit="34.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" lower_limit="-15.4" upper_limit="78.3"/>
                    <measurement group_id="O2" value="-22.5" lower_limit="-52.1" upper_limit="-8.8"/>
                    <measurement group_id="O3" value="-15.3" lower_limit="-30.2" upper_limit="60.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Leukocytes</title>
        <description>Percent change from baseline in leukocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 4, 8, 12, 16, 20 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Leukocytes</title>
          <description>Percent change from baseline in leukocytes, where the baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" lower_limit="-10.0" upper_limit="42.9"/>
                    <measurement group_id="O2" value="-24.9" lower_limit="-34.8" upper_limit="1.5"/>
                    <measurement group_id="O3" value="-14.9" lower_limit="-29.8" upper_limit="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" lower_limit="-18.3" upper_limit="38.6"/>
                    <measurement group_id="O2" value="-4.7" lower_limit="-26.4" upper_limit="11.4"/>
                    <measurement group_id="O3" value="0.7" lower_limit="-21.1" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="11.6" upper_limit="57.1"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-18.9" upper_limit="13.4"/>
                    <measurement group_id="O3" value="8.9" lower_limit="-14.0" upper_limit="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0" lower_limit="5.4" upper_limit="48.4"/>
                    <measurement group_id="O2" value="-15.4" lower_limit="-35.5" upper_limit="22.9"/>
                    <measurement group_id="O3" value="5.4" lower_limit="-24.2" upper_limit="38.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.0" lower_limit="14.6" upper_limit="53.7"/>
                    <measurement group_id="O2" value="-6.7" lower_limit="-26.9" upper_limit="27.0"/>
                    <measurement group_id="O3" value="15.2" lower_limit="-14.3" upper_limit="45.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="13.0" upper_limit="70.5"/>
                    <measurement group_id="O2" value="-27.5" lower_limit="-42.1" upper_limit="24.8"/>
                    <measurement group_id="O3" value="16.3" lower_limit="-32.8" upper_limit="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" lower_limit="0.2" upper_limit="75.3"/>
                    <measurement group_id="O2" value="18.3" lower_limit="-35.4" upper_limit="42.9"/>
                    <measurement group_id="O3" value="27.1" lower_limit="-26.4" upper_limit="63.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Markers of Iron Metabolism and Anemia - Blasts</title>
        <description>Change from baseline in % blasts at Weeks 2 and 4. The baseline % blasts value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2 and 4</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Markers of Iron Metabolism and Anemia - Blasts</title>
          <description>Change from baseline in % blasts at Weeks 2 and 4. The baseline % blasts value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">No blasts measured</measurement>
                    <measurement group_id="O2" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="3.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">No blasts measured</measurement>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Liver Iron Content</title>
        <description>Percent change from baseline in liver iron content assessed by MRI. The baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>Measured at Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Liver Iron Content</title>
          <description>Percent change from baseline in liver iron content assessed by MRI. The baseline value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7" lower_limit="-18.4" upper_limit="25.0"/>
                    <measurement group_id="O2" value="53.3" lower_limit="20.6" upper_limit="86.2"/>
                    <measurement group_id="O3" value="22.3" lower_limit="-6.0" upper_limit="71.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pharmacodynamics Biomarker - pSTAT3</title>
        <description>Percent change in %pSTAT stimulated CD3+/4+ T cell at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).</description>
        <time_frame>On Day 1 and at Weeks 4 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pharmacodynamics Biomarker - pSTAT3</title>
          <description>Percent change in %pSTAT stimulated CD3+/4+ T cell at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 - 2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.8" lower_limit="-34.2" upper_limit="-11.6"/>
                    <measurement group_id="O2" value="-13.5" lower_limit="-24.4" upper_limit="-7.6"/>
                    <measurement group_id="O3" value="-14.3" lower_limit="-27.7" upper_limit="-9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.1" lower_limit="-23.4" upper_limit="-8.1"/>
                    <measurement group_id="O2" value="-10.6" lower_limit="-30.6" upper_limit="-2.4"/>
                    <measurement group_id="O3" value="-12.8" lower_limit="-27.3" upper_limit="-6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" lower_limit="-16.9" upper_limit="-4.0"/>
                    <measurement group_id="O2" value="-4.3" lower_limit="-16.9" upper_limit="0.3"/>
                    <measurement group_id="O3" value="-7.1" lower_limit="-16.9" upper_limit="-2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-2.0" upper_limit="1.8"/>
                    <measurement group_id="O2" value="-2.9" lower_limit="-5.5" upper_limit="17.7"/>
                    <measurement group_id="O3" value="-2.0" lower_limit="-5.5" upper_limit="17.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" lower_limit="-21.9" upper_limit="-6.6"/>
                    <measurement group_id="O2" value="-20.0" lower_limit="-25.7" upper_limit="-7.4"/>
                    <measurement group_id="O3" value="-20.0" lower_limit="-25.7" upper_limit="-6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" lower_limit="-30.4" upper_limit="-8.8"/>
                    <measurement group_id="O2" value="-14.1" lower_limit="-28.7" upper_limit="-6.1"/>
                    <measurement group_id="O3" value="-14.1" lower_limit="-30.4" upper_limit="-6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.1" lower_limit="-29.0" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="-9.1" lower_limit="-12.9" upper_limit="4.9"/>
                    <measurement group_id="O3" value="-9.1" lower_limit="-19.0" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" lower_limit="-22.9" upper_limit="0.1"/>
                    <measurement group_id="O2" value="-0.3" lower_limit="-7.9" upper_limit="5.1"/>
                    <measurement group_id="O3" value="-2.8" lower_limit="-22.9" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.2" lower_limit="-51.2" upper_limit="-18.0"/>
                    <measurement group_id="O2" value="-10.7" lower_limit="-28.4" upper_limit="-10.1"/>
                    <measurement group_id="O3" value="-22.7" lower_limit="-48.2" upper_limit="-10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.6" lower_limit="-65.8" upper_limit="-17.6"/>
                    <measurement group_id="O2" value="-14.4" lower_limit="-22.6" upper_limit="-12.9"/>
                    <measurement group_id="O3" value="-22.6" lower_limit="-50.1" upper_limit="-14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" lower_limit="-33.2" upper_limit="-13.4"/>
                    <measurement group_id="O2" value="-10.1" lower_limit="-10.2" upper_limit="-4.9"/>
                    <measurement group_id="O3" value="-13.4" lower_limit="-24.8" upper_limit="-10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Pharmacodynamics Biomarker - pSTAT3/tSTAT3 Ratio</title>
        <description>Percent change in %pSTAT/%tSTAT Stimulated CD3+/4+ T cell ratio at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).</description>
        <time_frame>On Day 1 and at Weeks 4 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pharmacodynamics Biomarker - pSTAT3/tSTAT3 Ratio</title>
          <description>Percent change in %pSTAT/%tSTAT Stimulated CD3+/4+ T cell ratio at Day 1 (postdose), Week 4 and Week 24. The baseline value is defined as the last predose value from the baseline period prior to or on the date of first dose of momelotinib administration (Day 1 predose).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 - 2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.2" lower_limit="-38.9" upper_limit="-11.5"/>
                    <measurement group_id="O2" value="-15.5" lower_limit="-23.2" upper_limit="2.5"/>
                    <measurement group_id="O3" value="-13.4" lower_limit="-26.3" upper_limit="-3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.6" lower_limit="-23.2" upper_limit="-0.5"/>
                    <measurement group_id="O2" value="-9.7" lower_limit="-28.0" upper_limit="-2.3"/>
                    <measurement group_id="O3" value="-9.7" lower_limit="-23.9" upper_limit="-2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - 6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.1" lower_limit="-17.2" upper_limit="-5.7"/>
                    <measurement group_id="O2" value="-3.7" lower_limit="-12.1" upper_limit="3.7"/>
                    <measurement group_id="O3" value="-4.6" lower_limit="-13.7" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" lower_limit="-5.2" upper_limit="31.8"/>
                    <measurement group_id="O2" value="5.0" lower_limit="-4.3" upper_limit="39.8"/>
                    <measurement group_id="O3" value="4.8" lower_limit="-5.2" upper_limit="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" lower_limit="-17.5" upper_limit="20.3"/>
                    <measurement group_id="O2" value="-9.1" lower_limit="-22.6" upper_limit="9.6"/>
                    <measurement group_id="O3" value="-13.2" lower_limit="-22.6" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="-32.9" upper_limit="118.3"/>
                    <measurement group_id="O2" value="-13.4" lower_limit="-23.7" upper_limit="23.9"/>
                    <measurement group_id="O3" value="-13.4" lower_limit="-31.5" upper_limit="38.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 - 6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="-29.4" upper_limit="56.0"/>
                    <measurement group_id="O2" value="-6.1" lower_limit="-17.1" upper_limit="32.8"/>
                    <measurement group_id="O3" value="-6.1" lower_limit="-20.5" upper_limit="56.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - predose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.7" lower_limit="-17.4" upper_limit="-3.7"/>
                    <measurement group_id="O2" value="-3.5" lower_limit="-8.8" upper_limit="-2.8"/>
                    <measurement group_id="O3" value="-4.4" lower_limit="-17.4" upper_limit="-2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 2 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.7" lower_limit="-22.3" upper_limit="-15.4"/>
                    <measurement group_id="O2" value="-7.6" lower_limit="-22.1" upper_limit="-2.6"/>
                    <measurement group_id="O3" value="-16.2" lower_limit="-22.3" upper_limit="-2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 4 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.4" lower_limit="-27.1" upper_limit="-14.3"/>
                    <measurement group_id="O2" value="-11.5" lower_limit="-15.4" upper_limit="-9.6"/>
                    <measurement group_id="O3" value="-15.4" lower_limit="-27.0" upper_limit="-11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 - 6 hours postdose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.4" lower_limit="-22.8" upper_limit="-11.1"/>
                    <measurement group_id="O2" value="-6.5" lower_limit="-9.0" upper_limit="-5.1"/>
                    <measurement group_id="O3" value="-11.1" lower_limit="-20.0" upper_limit="-5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Inflammatory Markers - C-Reactive Protein (CRP)</title>
        <description>Percent change in C-reactive protein at Weeks 2, 12 and 24. The baseline C-reactive protein value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
        <time_frame>At Weeks 2, 12 and 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transfusion Independence Responders</title>
            <description>Subjects who became transfusion independent by Week 24</description>
          </group>
          <group group_id="O2">
            <title>Transfusion Independence Non-Responders</title>
            <description>Subjects who did not become transfusion independent by Week 24</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>All enrolled subjects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Inflammatory Markers - C-Reactive Protein (CRP)</title>
          <description>Percent change in C-reactive protein at Weeks 2, 12 and 24. The baseline C-reactive protein value is defined as the last value from the baseline period prior to or on the date of first dose of momelotinib administration (Baseline visit).</description>
          <units>% Change from baseline</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-68.7" lower_limit="-75.6" upper_limit="-43.5"/>
                    <measurement group_id="O2" value="-53.7" lower_limit="-76.8" upper_limit="-18.5"/>
                    <measurement group_id="O3" value="-55.6" lower_limit="-76.3" upper_limit="-29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-67.8" lower_limit="-73.1" upper_limit="-28.2"/>
                    <measurement group_id="O2" value="-43.4" lower_limit="-59.6" upper_limit="22.6"/>
                    <measurement group_id="O3" value="-48.9" lower_limit="-70.1" upper_limit="-15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-59.8" lower_limit="-79.1" upper_limit="-44.8"/>
                    <measurement group_id="O2" value="-47.1" lower_limit="-68.4" upper_limit="65.3"/>
                    <measurement group_id="O3" value="-54.8" lower_limit="-73.8" upper_limit="-30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the first dose of momelotinib until 30 days following the last dose.</time_frame>
      <desc>All adverse events summarized were treatment-emergent, defined as any adverse event with an onset date on or after the momelotinib start date and no later than 30 days after permanent discontinuation of momelotinib or any adverse event leading to premature discontinuation of momelotinib.</desc>
      <group_list>
        <group group_id="E1">
          <title>Momelotinib (MMB)</title>
          <description>Subjects received oral MMB at a starting dose of 200 mg once daily for 24 weeks (± 7 days) on study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Most restrictive: Site may not present or publish results of Trial without advance written notice of Sponsor or two years after completion of Trial at all participating sites. Site must submit all proposed publications or presentations to Sponsor for review. Sponsor can review communications prior to public release and embargo trial results communications for a period between 75 and 180 days from submission to Sponsor for review. Sponsor has right to request Site remove Confidential Information.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Pharmacokinetics parameters were removed as an analysis endpoint in the SAP due to the sparse PK samples collection.&#xD;
Change in circulating cytokine and inflammatory markers were limited to CRP as an analysis endpoint in the SAP.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Barbara Klencke</name_or_title>
      <organization>Sierra Oncology, Inc.</organization>
      <phone>1-604-558-6536</phone>
      <email>bklencke@sierraoncology.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

